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esponsibility of InstAbstract Nitroreductases (NTRs) are known to be able to metabolize nitro-substituted compounds in the
presence of reduced nicotinamide adenine dinucleotide (NADH) as an electron donor. NTRs are present in a
wide range of bacterial genera and, to a lesser extent, in eukaryotes hypoxic tumour cells and tumorous
tissues, which makes it an appropriate biomarker for an imaging target to detect the hypoxic status of cancer
cells and potential bacterial infections. To evaluate the specific activation level of NTR, great efforts have
been devoted to the development of fluorescent probes to detect NTR activities using fluorogenic methods to
probe its behaviour in a cellular context; however, NTR-responsive MRI contrast agents are still by far
underexplored. In this study, para-nitrobenzyl substituted T1-weighted magnetic resonance imaging (MRI)
contrast agent Gd-DOTA-PNB (probe 1) has been designed and explored for the possible detection of NTR.
Our experimental results show that probe 1 could serve as an MRI-enhanced contrast agent for monitoring
NTR activity. The in vitro response and mechanism of the NTR catalysed reduction of probe 1 have been
investigated through LC–MS and MRI. Para-nitrobenzyl substituted probe 1 was catalytically reduced by
NTR to the intermediate para-aminobenzyl substituted probe which then underwent a rearrangementl Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Schem
Yun Liu et al.402elimination reaction to Gd-DOTA, generating the enhanced T1-weighted MR imaging. Further, LC–MS and
MRI studies of living Escherichia coli have confirmed the NTR activity detection ability of probe 1 at a
cellular level. This method may potentially be used for the diagnosis of bacterial infections.
& 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Molecular imaging provides a sensitive and specific method for non-
invasive, real-time monitoring and visualization of biological pro-
cesses in vivo1–4. Magnetic resonance imaging (MRI) has several
advantages over other clinical diagnostic techniques for molecular
imaging, in virtue of its high spatial resolution, unlimited penetration
depth, and lack of harmful radiation5–7. Over the past three decades,
paramagnetic Gd(III) complexes have been widely developed as
contrast agents to dramatically improve detection sensitivity and
specificity of MRI by shortening the relaxation times of the
surrounding water proton resulting in an enhanced imaging con-
trast8–11. At present, the contrast agents most commonly used in
clinical MRI are mainly small molecule gadolinium chelates, such as
Magnevist (Gd-DTPA), Dotarem (Gd-DOTA), ProHance (Gd-HP-
DO3A), etc. To further improve the enhancing effects and detect
physiological changes at the molecular level, the smart MRI contrast
agents have been developed and used12–15. These probes are capable
of monitoring physiological processes by changing signal properties
with changes in the physiological environment, such as enzyme16–20,
metal ion concentration20–23, pH value24,25, temperature26, etc.
Recently, applications of enzyme-activatable MRI contrast agents
have been reported.
Nitroreductases (NTRs), are a family of flavin-containing
enzymes widely exists in bacteria, which can effectively catalyze
the reduction of nitroaromatic compounds into hydroxylamines or
amines in the presence of reduced nicotinamide adenine dinucleo-
tide (NADH) or nicotinamide adenine dinucleotide phosphate
(NADPH) as a cofactor via an one-electron reduction path-
way27–31. An increasing number of nitroaromatic compounds have
proved to be superior substrates for NTRs opening up the
opportunity to develop enzyme-activatable probes, which is, given
the role of the NTRs of great significance for environmental and
human health32–34. Great effort has been devoted to the design of
activatable optical probes for sensing NTR activities within
hypoxic tumor cells; lately, optical probes for detecting NTR
activities in bacterial lysates have been developed as well33–38. In
comparison, a few NTR-activatable MRI contrast agents have been
developed39,40, and there appears to have been no real time NTR
enzymatic activity detection in bacteria using an MRI method.
In this study, we designed and synthesized a novel NTR-enhanced
MRI contrast agent: Gd-DOTA-PNB (probe 1) by conjugating Gd-e 1 Structure and reaction respoDOTA with an NTR-sensing moiety, a p-nitrobenzyl group. Probe 1
has been characterized by 1H NMR, 13C NMR, MS and evaluated as
a new NTR-enhanced MRI contrast agent, which may potentially be
used for the diagnosis of bacterial infections. Conceptually, we
hypothesized that the p-nitrobenzyl moiety (PNB) of probe 1 would
be reduced to a primary aromatic amino group by NTR in the
presence of NADH, which would then trigger a self-immolative
fragmentation through a rearrangement elimination reaction and
formation of Gd-DOTA (Scheme 1) resulting a relaxivity enhance-
ment, which could be used for NTR activities detection. The in vitro
response and mechanism of the NTR catalysed reduction of probe 1
have been investigated through LC–MS and MRI. Further, LC–MS
and MRI studies of living Escherichia coli (E. coli) have confirmed
the NTR activity detection ability of probe 1 at a cellular level, which
hint to the potential application of probe 1 for the diagnosis of
bacterial infections.
2. Materials and methods
2.1. General methods
All chemicals were purchased from J&K (Beijing, China).
Commercially available reagents were used without further pur-
ification. Unless otherwise noted, all reactions were performed
under a nitrogen or argon atmosphere. NTR (Z 100 units/mg)
from E. coli, and NADH were purchased from Sigma–Aldrich
(Shanghai, China). The lyophilized powder of NTR was dissolved
in pure water, and the solution was divided into aliquots suitable
for daily experiments. All these enzyme solutions were stored at
−20 °C and allowed to thaw before use according to the reported
procedure, under the premise of no change of the enzyme
activity33,34. A stock solution (10 mmol/L) for compounds 1 and
2 were prepared by dissolving an appropriate amount of them in
H2O. The E. coli (ATCC 25922) was purchased from American
Type Culture Collection (ATCC), USA. MTS (3-(4,5-di-
methylthiazol-2-yl)-5(3-carbo-xymethoxyphenyl)-2-(4-sulfo-
pheny)-2H-tetrazolium, inner salt) was obtained from Promega
(Beijing, China). OD values and MTS assays were also measured
by TECAN Spark 10 M microplate reader (Männedorf, Switzer-
land). Thin layer chromatography (TLC) was carried out with
Silica Gel 60 F254, and column chromatography with silica gel
(200–300 mesh). All 1H NMR spectra were recorded at 600 MHznse mechanism of probe 1 to NTR.
Scheme 2 Synthesis of probe 1. (a) bromoacetyl bromide, DMAP, toluene, 92%. (b) t-Butyl bromoacetate, sodium acetate, DMA, 62%.
(c) Compound 3, K2CO3, MeCN, 89%. (d) TFA/ triethylsilane/H2O, 0 °C, 63%. (e) GdCl3·6H2O, NaOH, pH 6.5–7.0, 61%.
A nitroreductase-enhanced MRI contrast agent for bacterial imaging 403and 13C NMR spectra were recorded at 150 MHz respectively
(Varian VNS, 600 MHz, USA). Mass spectra (MS) were measured
with an Exactive Plus Orbitrap mass spectrometer via an ESI
interface (ThermoFisher Scientific, Bremen, Germany). Character-
ization of MR properties were measured at a Pharmscan 70/16
USmagnetic resonance imaging scanner (Bruker, Switzerland)
fitted with RF RES 300 1H 089/072 QSN TR AD volume coil.
2.2. Analysis and determination of the conversion kinetics by
LC–MS
To investigate the kinetics of the NTR-catalyzed reaction of probe
1, the conversion reaction mixture containing probe 1 (200 μmol/
L), NTR (30 μg/mL) and NADH (500 μmol/L) at 37 °C in 0.9%
aqueous NaCl solution was analyzed. The reaction was performed
in a 0.5 mL eppendorf tube with a reaction volume of 50 μL at
different time points (0, 3, 6, 12 and 24 h) and quenched by
addition of acetonitrile (60 μL). After centrifugation at 6500 rpm
for 3 min (HC-2062 High speed centrifuge, Anhui USTC Zonkia
Scientific Instruments Co., Ltd., Hefei, China), the supernatants
were analyzed by LC–MS. The conversion rate of 1 to Gd-DOTA
(2) following the enzymatic reaction was calculated according to
the percentage of peak area of 1. Pseudo-first-order rate constants
for enzymatic hydrolysis were determined based on the equation
y¼A0×e–x/t (where A0¼1 and t−1¼kobs), using GraphPad Prism 5
(GraphPad Software Inc., USA).
2.3. Determination of the enzymatic reaction in vitro by an
HPLC assay
The specific enzymatic reaction of probe 1 to NTR was conducted
in 0.9% aqueous NaCl solution. Four aqueous solutions were
prepared: (A) 200 μmol/L probe 1 and 500 μmol/L NADH in 0.9%
aqueous NaCl solution; (B) 200 μmol/L probe 1, 500 μmol/L
NADH, and 30 μg/mL NTR in 0.9% aqueous NaCl solution;
(C) 200 μmol/L probe 1, 500 μmol/L NADH, 30 μg/mL NTR and
0.25 mmol/L dicoumarin in 0.9% aqueous NaCl solution;
(D) 200 μmol/L probe 1, 500 μmol/L NADH, 30 μg/mL NTR
and 0.5 mmol/L dicoumarin in 0.9% aqueous NaCl solution.
Reactions were performed for 6 h at 37 °C, and quenched by
adding CH3CN (250 μL). Then, after centrifugation the super-
natants (6500 rpm, 3 min) were measured by high performance
liquid chromatography (HPLC) equipped with an evaporative light
scattering detector (ELSD). The HPLC method was as follows:
mobile phase A was acetonitrile with 0.1% trifluoroacetic acid, and
mobile phase B consisted of water with 0.1% trifluoroacetic acid; alinear gradient was set from 1% to 5% B in 10 min, followed by a
gradient to 90% B in 10 min, then at 90% B for 2 min; the flow
rate was 1.0 mL/min, and 50 μL of sample was injected. The
conversion rate of 1 to Gd-DOTA following the enzymatic
reaction was calculated according to the percentage of peak area
of 1 before incubation.
2.4. Bacteria and cell culture
E. coli (ATCC 25922) was used in this study. The Luria-Bertani (LB)
culture medium was prepared by dissolving 10 g bacto-tryptone, 5 g
bactoyeast extract and 5 g NaCl in 1 L water. The culture medium
was autoclaved prior to use. For determining the NTR activity
generated by E. coli, single colony from the stock agar plate was
added to 20 mL of LB culture media, which then was grown at 37 °C
on a shaker incubator (180 rpm, THZ-C-1, Suzhou, China) overnight
followed by a subculture until an OD600 of approximately 5–7 was
reached. The Raw 264.7 cells, 293 A cells, rat fibroblast L6 cells and
HepG2 cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) with 10% fetal bovine serum (FBS) under humidified
atmosphere of 5% CO2 at 37 °C.
2.5. In vitro LC–MS/ELSD measurement of the conversion and
selectivity of probe 1 incubated with bacteria
E. coli cells were cultured for 12 h in LB culture media at 37 °C.
Bacterial strains cultured overnight was harvested and washed
three times with 0.9% aqueous NaCl solution. The washed cells
were resuspended in 0.9% aqueous NaCl solution with an OD600
of 5–7 and were divided into 500 μL aliquots. The following
samples were set up: (A) probe 1 (200 μmol/L) only, (B) cells
treated with probe 1 (200 μmol/L), (C) cells treated with probe 1
(200 μmol/L) and dicoumarin (0.5 mmol/L). After incubation at
37 °C for 24 h, 500 μL CH3OH were added and the samples
subjected to subsequent ultrasonication using an ultrasonic cell
disintegrator (SONIC-VCX-130, USA). Then after centrifugation
(6500 rpm, 3 min) the supernatants were measured by HPLC–ESI-
MS and HPLC–ELSD analyses.
2.6. Longitudinal relaxation time (T1) measurement
The longitudinal relaxation time (T1) of the Gd(III) complexes in
different solutions was measured using the standard inversion
recovery spin-echo sequence on 7 T scanner operating at 300 MHz
and room temperature (Pharmscan 70/16 US, Bruker, Switzer-
land). For acquisition of T1 relaxation time, a T1 map rapid-
Figure 1 (a) Plot of reduction of probe 1 with (red) or without (blue) NTR at 37 °C (in 0.9% aqueous NaCl solution) monitored by LC–MS.
Individual data points represent the integration of the peak area of probe 1 post-incubation with or without NTR divided by the peak area of probe
1 before incubation (multiplied by 100 to give percent complex hydrolysis). The red line corresponds to a pseudo first-order kinetic fit of the data
with a half-life of t1/2¼2.56 h for 1. Data are mean7SD (n¼2). (b) Conversion of 1 (200 μmol/L) to various species: control (probe 1), NTR
(30 μg/mL), GSH (1 mmol/L), DTT (1 mmol/L), Cys (1 mmol/L), Hcy (1 mmol/L).
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used. The following parameter values were utilized: static echo
time¼8 ms, variable repetition time¼200, 400, 800, 1500, 3000,
and 5500 ms, field of view¼50×50 mm2, matrix size¼256×192,
number of axial slices¼1, slice thickness¼1.0 mm, and
averages¼1. Paravision 6.0 software (Bruker) was used for T1
analysis, by mono-exponential curve-fitting of image intensities of
selected regions of interest (ROIs) from the axial slice.
2.7. Characterization of the MR properties in vitro
To determine relaxivity (r1) of probe 1 and Gd-DOTA in different
solutions, a 10 mmol/L stock solution of either probe 1 or Gd-
DOTA in the appropriate buffer was diluted to give 500 μL of
each of seven concentrations for each run: 0, 0.1, 0.2, 0.4, 0.6, 0.8,
and 1.0 mmol/L. The values of r1 (mM
-1 s-1) were determined
from the slope of the linear fit of the relaxation rate (1/T1, s
−1)
plotted against the compound concentration (mmol/L). All lines
were fitting with R240.997.
To study the effect of the NTR reduction on the T1 value of
probe 1, NTR was dissolved in water to form an aqueous solution.
For the T1 measurements of probe 1 in the presence or absence of
NTR and NADH, the follow reactions were set up: (a) 200 μmol/L
probe 1 in 0.9% aqueous NaCl solution; (b) 200 μmol/L probe 1
and 500 μmol/L NADH in 0.9% aqueous NaCl solution;
(c) 200 μmol/L probe 1, 500 μmol/L NADH, and 30 μg/mL
NTR in 0.9% aqueous NaCl solution. The T1 of these solutions
were measured after incubation for 12 h at 37 °C.
2.8. In vitro MR imaging of E. coli treated with probe 1
E. coli cells were cultured for 12 h in LB culture media at 37 °C.
Bacterial strains cultured overnight were harvested and washed
three times with 0.9% aqueous NaCl solution. The washed cells
were resuspended in 0.9% aqueous NaCl solution until an OD600
of 6 was reached. Then 500 μL aliquots (5.1×109 CFU/mL) were
(A) untreated, (B) treated with 200 μmol/L of probe 1 for 0 h and
(C) treated with 200 μmol/L of probe 1 for 24 h. After incubation
at 37 °C for 24 h, the samples were imaged using a RF RES 300
1 H 089/072 QSN TR AD volume coil (Pharmscan 70/16 US,
Bruker, Switzerland). For acquisition of T1 relaxation times, a T1
map rapid acquisition with refocused echoes (T1 map RARE) pulse
sequence was used. For T1-weighting, the following parameters
were used: TR¼400 ms, TE¼8 ms, flip angle¼90°, NEX¼1,FOV¼55×55 mm2, slice thickness¼1 mm, and matrix
size¼256×192.2.9. Cytotoxicity assays
The cytotoxicity of probe 1 was evaluated following the approach
reported previously.3 The Raw 264.7 cells, 293 A cells, rat
fibroblast L6 cells and HepG2 cells were seeded on a 96-wells
containing 7500 cells per well in 100 μL DMEM media and
incubated for overnight before adding probe 1. Upon incubation
with different concentration of probe 1 at 37 °C for 48 h, then
incubated with cell culture medium containing 20% MTS per well.
After 3 h of incubation at 37 °C, the absorbance was measured at
490 nm using a TECAN Spark 10 M microplate reader. Cell
viabilities at various concentrations are given as a percentage of
control sample without probe. Each experiment was repeated three
times. The cell survival rate from the control group was considered
to be 100%.3. Results and discussion
3.1. Synthesis of the Gd(III) complexes
The Gd(III) complexes of probe 1 and Gd-DOTA (2) were
synthesized as shown in Scheme 2. 2-(4-Nitrobenzyl)-bromo-
acetate (3) was synthesized via alkylation-coupling reactions
between 4-Nitrobenzyl alcohol and bromoacetyl bromide in the
presence of DMAP and toluene in 92% yield without further
purification. The bromoacetyl group was used as a linker to
connect the DO3A-tris-tert-butyl ester (4) and 4-nitrobenzyl
alcohol. Subsequently, the tert-butyl groups in DOTA were
removed with TFA/trimethylsilane/H2O (98:1:1) to obtain
DOTA-PNB (6). The ligand, DOTA-PNB (6), was characterized
by ESI-MS and NMR, and its purity was determined by HPLC to
be greater than 98% (Supplementary information Fig. S1). Finally,
the ligands DOTA-PNB and DOTA were reacted with
GdCl3·6H2O in water at pH 6.5–7.0 to give Gd-DOTA-PNB
(probe 1) and Gd-DOTA, respectively. Probe 1 was obtained in
61% yield, while Gd-DOTA was obtained in 13% yield due to the
lack of a chromophore on Gd-DOTA for spectrometric detection
which was hampering the experimental isolation procedure.
Figure 2 (a) HPLC traces of different reaction systems. (A): 200 μmol/L probe 1 and 500 μmol/L NADH in 0.9% aqueous NaCl solution
(control); (B): system (A) þ 30 μg/mL NTR; (C): system (B) þ 0.25 mmol/L dicoumarin; (D): system (B) þ 0.5 mmol/L dicoumarin. All the
reactions were performed at 37 °C for 6 h. (b) The percentage of probe 1 in different reaction systems A, B, C, D. The control (A) was considered
to be 100%. Data are mean7SD (n¼3).
Figure 3 (a) HPLC traces of different reaction systems. (A): probe 1 (200 μmol/L) in 0.9% aqueous NaCl solution (control); (B): system (A) þ
E. coli (OD600¼6.2); (C): system (B) þ dicoumarin (0.5 mmol/L). All the reactions were performed at 37 °C for 24 h. (b) The percentage of probe
1 in different reaction systems A, B, C. The control (A) was considered to be 100%. Data are means 7SD(n¼3).
Figure 4 T1 relaxivity of probe 1 (1) and Gd-DOTA (2) at 300 MHz,
r.t., a10 mmol/L PBS, pH¼5.35; b0.9% aqueous NaCl solution.
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LC–MS is a convenient and practical method to detect and identify
the products of enzyme-catalyzed reaction41,42. To monitor the
ability of the NTR to activate the probe 1, the reaction mixture was
analyzed by LC–MS after incubating probe 1 (200 μmol/L) with
NTR (30 μg/mL) and NADH (500 μmol/L) at 37 °C in 0.9%
aqueous NaCl solution (Supplementary Information Fig. S2).
Probe 1 and its product Gd-DOTA are readily discriminated by
their appropriate positive mode ESI-MS, and through spiking with
authentic compound. The ESI-MS spectrum of the reaction
solution definitely displays the presence of Gd-DOTA as a major
product at 3.77 min (m/z¼559.10, [MþH]þ). Unreacted probe 1
decreased markedly at 19.76 min (m/z¼695.14, [MþH]þ) after
3 h, which was disappeared after 24 h (Supplementary information
Figs. S2–3). Moreover, the kinetics of NTR reaction were
investigated by following the decrease of probe 1 post-incubation
with NTR at 37 °C in 0.9% aqueous NaCl solution (Fig. 1a). After
20 h, 99.5% of 1 was hydrolyzed resulting in a rate constant of
7.52 × 10−5 s−1 (kobs, 37 °C) by assuming a pseudo first-order
kinetics. This rate constant corresponds to a half-life of t1/
2¼2.56 h. Therefore, all these data indicate that the reaction most
likely undergoes the proposed reduction-elimination mechanism as
shown in Scheme 1. Considering the complexity of the intracel-
lular environment, the interferences of various biothiols (GSH,
DTT, cysteine and homocysteine) were studied. As shown in
Fig. 1b, the probe shows high selectivity for NTR over the other
species tested, even including reductive biothiols at a high
concentration, which may be ascribed to the specific reduction
of the substrate (p-nitrobenzyl) by the enzyme.3.3. In vitro HPLC assay of enzymatic reaction
Having established the activation mechanism of probe 1, we then
evaluated whether probe 1 is specific for NTR. To study the
selectivity of probe 1 for NTR, the effect of the known competitive
inhibitor dicoumarin33,36 of NTR on the activity of the enzyme
was examined using high performance liquid chromatography
(HPLC) equipped with an evaporative light scattering detector
(ELSD) (Fig. 2 and Supplementary information Fig. S4). As
shown in Fig. 2a, HPLC chromatograms of probe 1 (200 μmol/L)
incubated with NADH (500 μmol/L), NTR (30 μg/mL), and the
NTR inhibitor dicoumarin (0.25/0.5 mmol/L) for 6 h at 37 °C in
0.9% aqueous NaCl solution were monitored. On incubation with
NTR in reaction system, probe 1 (tR¼16.8 min) was efficiently
Figure 5 MR studies with probe 1 upon activation with NTR in vitro. (a) T1 value reduction of probe 1 (200 μmol/L) in the presence of NADH
(500 μmol/L) and NTR (30 μg/mL) in 0.9% aqueous NaCl solution at 37 °C. (b) Change percentage in R1 (1/T1) of NTR-catalyzed hydrolysis of
probe 1. T1 value was measured with a Pharmscan 70/16 US (Bruker, Switzerland) imaging scanner at r.t., using the standard inversion recovery
program. Data represent mean value7SD, n¼2.
Figure 6 Cellular MR studies of incubating with probe 1. (a) T1 values (7 T) of E. coli cell pellets after incubation with 200 μmol/L of probe 1
for 0 or 24 h. (b) T1-weighted MR images (7 T, TE/TR¼8/400 ms) of E. coli cell pellets after incubation with 200 μmol/L of probe 1 for 0 h or 24
h. Data are means7SD (n¼3).
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completely reduced after 6 h. In contrast, residual content probe 1
in the presence of 0.25 mmol/L dicoumarin (curve/bar graph C)
indicated by the peak area is much larger than the content of 1
(curve/bar graph B) in the absence of the inhibitor after 6 h. Higher
concentration of dicoumarin (0.5 mmol/L) resulted increased
remaining probe 1 content after 6 h (curve/ bar graph D) roughly
equally to the control reaction without NTR (incubation of probe 1
with only NADH, curve/ bar graph A, Fig. 2b). We conclude that
the NTR activity can be effectively inhibited by dicoumarin, and
thus the reduction of probe 1 to NTR is indeed attributed to the
enzyme catalyzed cleavage reaction, confirming the good selec-
tivity of probe 1 for NTR detection.3.4. In vitro LC–MS/ELSD assay of probe 1 incubated with
bacteria
It is known that E. coli can generate NTR, and this bacterial enzyme
has been considered to be useful for the removal of nitroaromatic
pollutants27,28,30,43. To study whether the probe 1 could detect
microbial NTR activity at a cellular level, we measured the time
dependent conversion of probe 1 (200 μmol/L) in E. coli for 24 h by
HPLC chromatograms and ESI-MS spectra (Fig. 3 and
Supplementary Information Fig. S5). Fig. 3a shows HPLC chroma-
tograms of probe 1 at 16.7 min, which indicates that the peak area of
probe 1 after incubating with E. coli (curve/bar graph B) is less than
that (curve/bar graph A) in the absence of the bacteria, while addition
of dicoumarin (0.5 mmol/L) to the bacterial culture before treatment
with the probe 1 (curve/bar graph C) significantly decrease thereduction rate of probe. By calculating percentage of probe 1, we
discover that probe 1 is reduced about 80% after incubating with E.
coli, and decreasing to about 50% by the addition of the NTR
inhibitor dicoumarin (Fig. 3b). Moreover, the ESI-MS spectrum of
probe 1 under the above conditions is shown in Supplementary
Information Fig. S5. Here, the peak area change of probe 1 in the
MS spectrum is consistent with the peak area change of Fig. 3. This
result shows that probe 1 can be reduced by NTR of E. coli and the
reduction can be inhibited by the NTR inhibitor dicoumarin,
demonstrating the activation specificity of the probe 1 towards
NTR. Taken together, this suggest that probe 1 may be used as a
microbial growth indicator.3.5. Relaxometric studies of the Gd(III) complexes in vitro
The efficiency of MR contrast agent is defined according to the
parameter relaxivity (r1), which is a weigh of the extent to which the
paramagnetic compound (per concentration unit), shortens the long-
itudinal relaxation time (T1) of water protons.
5 To study relaxometric
properties of the probe, the longitudinal relaxivity (r1) values of
probe 1 and the predicted reduction product, Gd-DOTA (2), are
determined at 7 T, 300 MHz and room temperature (Fig. 4 and
Supplementary information Fig. S6). As shown in Fig. 4, the r1
value of Gd-DOTA in PBS buffer (pH ¼ 5.35) is 4.02 mM-1 s-1,
which is 15% higher than that of 1 (3.51 mM-1 s-1). Owing to
enzyme reaction in 0.9% aqueous NaCl solution, the relaxivities of
probe 1 and Gd-DOTA were also determined under these conditions.
Here, the relaxivities of probe 1 and Gd-DOTA were 3.16 mM-1 s-1
and 3.61 mM-1 s-1 respectively, which are lower than observed in
A nitroreductase-enhanced MRI contrast agent for bacterial imaging 407PBS buffer but show the same trend with a 14% rise in relaxivity
from probe 1 to Gd-DOTA. In this case, the phosphate could
coordinate to DO3A analogues in a monodentate fashion17,44,45 and
compete with intramolecular coordination, then increase the number
of water molecules coordinated to the metal center. Therefore, the
relaxivities in PBS buffer are expected to be higher than that in 0.9%
aqueous NaCl solution. In addition, the difference in r1 relaxivity
between probe 1 and Gd-DOTA can provide the evidence for study
of MRI contrast agent probe 1 reduced by NTR.
To evaluate probe 1 as a potential NTR-responsive MRI contrast
agent, probe 1 (200 μmol/L) was incubated with NADH (500 μmol/
L) and NTR (30 μg/mL) at 37 °C for 12 h in 0.9% aqueous NaCl
solution and the change in the longitudinal relaxation time (T1) was
evaluated. We observed that the T1 value of probe 1 is 89775 ms,
while the T1 is 84379 ms decreased by 6% in the presence of NTR,
which is consistent with the relaxometric study (Fig. 5). The changes
in T1 values can be explained the significant increase of product 2
(Gd-DOTA) upon enzymatic cleavage of probe 1 over time after
NTR treatment, resulting in a decrease in the longitudinal relaxation
time (T1). We conclude that probe 1 can therefore selectively
respond to NTR and detect its activity in an MRI setting. Moreover,
under optimized conditions (reaction at 37 °C for 6 h in 0.9%
aqueous NaCl solution in the presence of 500 μmol/L NADH), the
T1 values of probe 1 (200 μmol/L) to NTR at different concentrations
is shown in Supplementary Information Fig. S7a. As can be seen, a
gradual decrease in T1 value is observed with increase in the NTR
concentrations, and a good linearity is obtained in the range of 5 to
40 μg/mL (Supplementary Information Fig. S7b), with the regression
equation T1 ¼−1.0474×[c]μg/mLþ894.82 (R2¼0.9926). The
detection limit is determined to be 24 ng/mL NTR.
3.6. In vitro MR imaging of E. coli treated with probe 1
In addition, MR imaging was performed to evaluate the efficiency of
probe 1 for detecting endogenous NTR activity in E. coli. The
experiments were carried out at 7 T using three incubations:
(A) bacteria alone, (B) bacteriaþprobe 1, incubated for 0 h,
(C) bacteriaþprobe 1, incubated for 24 h. As shown in Fig. 6a, the
T1 value of E. coli after incubation with 1 (200 μmol/L) for 24 h is
81975 ms reduced by 8% as compared to 0 h (88572 ms). The
shorter T1 value was again consistent with the results of the T1-
weighted images of bacteria shown in Fig. 6b, where E. coli after
incubation with 1 for 24 h manifested higher MR signal intensity than
at 0 h. The results of in vitro MR imaging studies of E. coli treated
with probe 1 indicated that probe 1 could permeate E. coli cell
membrane and be subsequently activated by the NTR, leading to an
enhanced MRI contrast. Our experimental results show that probe 1
could serve as an MRI-enhanced contrast agent for monitoring NTR
activity in living bacteria. Considering NTRs are also present in
eukaryotes hypoxic tumour cells, MR imaging hypoxia was per-
formed in Hela cells by probe 1. In this experiment, Hela cells (1 ×
106) were incubated with 200 μmol/L probe 1 under hypoxic
conditions (1% pO2) at 37 °C for 0 h or 24 h. As shown in
Supplementary Information Fig. S8, Hela cells treated with probe 1
for 24 h show shorter T1 value (85878 ms) by 6% than 0 h
(91472 ms), which are not as obvious as that in E. coli.
3.7. Cytotoxicity of probe 1
Finally, we evaluated the cytotoxicity of probe 1 using standard
MTS assays to further qualify our probe for in vivo studies andexclude any detrimental interfering effects in our cellular studies.
As shown in Supplementary Information Fig. S9, after incubation
with probe 1 for 48 h, the viability of the cells showed no
significant change, and approximately 80% of cells survived even
at the very high concentration of 500 μmol/L of probe 1. The
results indicate that our probe 1 has a low cytotoxicity and good
biocompatibility.4. Conclusions
In conclusion, we have designed and synthesized an NTR-
enhanced MRI contrast agent, probe 1, which is convenient for
the detection of NTR activity in vitro and in living E. coli. The
para-nitrobenzyl moiety of probe 1 can be selectively reduced by
NTR in the presence of NADH, followed by a self-immolative
fragmentation, and formation of the Gd-DOTA, which was
confirmed by LC–MS and HPLC analyses. Furthermore, relaxo-
metric measurements revealed that the longitudinal T1 relaxivity of
probe 1 is different from Gd-DOTA and thus changes in
concentration of both species are detectable by MRI. The long-
itudinal relaxation time (T1) was decreased by 6% in response to
NTR. More importantly, MR images studies of living E. coli
incubated with probe 1 resulted an 8% signal intensity enhance-
ment, which indicates that probe 1 could serve as an MRI-
enhanced contrast agent for monitoring NTR activity. Probe 1 is
the first reported smart MRI contrast agents for monitoring NTR
activity in living bacteria, which has the potential for a wider
application in therapeutic NTR-activated prodrug treatment in
clinical research.
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